667 related articles for article (PubMed ID: 21068341)
1. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.
Cannon JA; Shen L; Jhund PS; Anand IS; Komajda M; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2016 Aug; 18(8):1021-31. PubMed ID: 27194023
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
[TBL] [Abstract][Full Text] [Related]
5. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
[TBL] [Abstract][Full Text] [Related]
6. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
[TBL] [Abstract][Full Text] [Related]
7. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
[TBL] [Abstract][Full Text] [Related]
8. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
Krum H; Elsik M; Schneider HG; Ptaszynska A; Black M; Carson PE; Komajda M; Massie BM; McKelvie RS; McMurray JJ; Zile MR; Anand IS
Circ Heart Fail; 2011 Sep; 4(5):561-8. PubMed ID: 21750125
[TBL] [Abstract][Full Text] [Related]
9. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Shah RV; Desai AS; Givertz MM
J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
Gandhi PU; Chow SL; Rector TS; Krum H; Gaggin HK; McMurray JJ; Zile MR; Komajda M; McKelvie RS; Carson PE; Januzzi JL; Anand IS
J Card Fail; 2017 Jan; 23(1):20-28. PubMed ID: 27317843
[TBL] [Abstract][Full Text] [Related]
11. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
Carson P; Massie BM; McKelvie R; McMurray J; Komajda M; Zile M; Ptaszynska A; Frangin G;
J Card Fail; 2005 Oct; 11(8):576-85. PubMed ID: 16230259
[TBL] [Abstract][Full Text] [Related]
12. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
Badar AA; Perez-Moreno AC; Hawkins NM; Jhund PS; Brunton AP; Anand IS; McKelvie RS; Komajda M; Zile MR; Carson PE; Gardner RS; Petrie MC; McMurray JJ
Circ Heart Fail; 2015 Jul; 8(4):717-24. PubMed ID: 26067854
[TBL] [Abstract][Full Text] [Related]
14. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
Haass M; Kitzman DW; Anand IS; Miller A; Zile MR; Massie BM; Carson PE
Circ Heart Fail; 2011 May; 4(3):324-31. PubMed ID: 21350053
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.
Zile MR; Gottdiener JS; Hetzel SJ; McMurray JJ; Komajda M; McKelvie R; Baicu CF; Massie BM; Carson PE;
Circulation; 2011 Dec; 124(23):2491-501. PubMed ID: 22064591
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
Lam CS; Carson PE; Anand IS; Rector TS; Kuskowski M; Komajda M; McKelvie RS; McMurray JJ; Zile MR; Massie BM; Kitzman DW
Circ Heart Fail; 2012 Sep; 5(5):571-8. PubMed ID: 22887722
[TBL] [Abstract][Full Text] [Related]
17. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
[TBL] [Abstract][Full Text] [Related]
18. Irbesartan in patients with heart failure and preserved ejection fraction.
Massie BM; Carson PE; McMurray JJ; Komajda M; McKelvie R; Zile MR; Anderson S; Donovan M; Iverson E; Staiger C; Ptaszynska A;
N Engl J Med; 2008 Dec; 359(23):2456-67. PubMed ID: 19001508
[TBL] [Abstract][Full Text] [Related]
19. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
[TBL] [Abstract][Full Text] [Related]
20. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
